Empagliflozin vs. DPP-4 inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German claims data analysis

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/45480
• EU PAS number:
  EUPAS31950
• Study ID:
  45480
• Official title and acronym:
  Empagliflozin vs. DPP-4 inhibitors and GLP-1 Receptor Agonists Cost of Care Study: a German claims data analysis
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  Study design: - Retrospective non-interventional comparative cost study using real-world data German sickness funds (claims). Research question and objectives: - Comparison of direct and indirect healthcare cost of type-2 diabetes mellitus (T2D) patients treated with Empagliflozin vs. DPP-4 Inhibitors (DPP-4i) / Sitagliptin or GLP-1 receptor agonists (GLP-1-RA) - Assessment of characteristics as well as previous and concomitant treatments of T2D patients treated with Empagliflozin or DPP-4i / Sitagliptin or GLP-1-RA
• Study status:
  Ongoing

Research institutions and networks

Institutions

Institut für Pharmakoökonomie und Arzneimittellogistik (IPAM)

Study timelines

Date when funding contract was signed

Planned: 31/10/2019

Study start date

Planned: 03/02/2020

Actual: 16/11/2020

Date of final study report

Planned: 30/06/2022

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable